If You Invested in Myriad Genetics (MYGN)

Myriad Genetics, Inc. (NASDAQ: MYGN) is a molecular diagnostic testing and precision medicine company in the pharmaceutical preparation manufacturing industry. According to multiple company disclosures, Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can improve patient care and lower healthcare costs.

The company’s business centers on laboratory-developed and regulated molecular diagnostic tests that provide genetic and genomic information to clinicians. These tests are used in areas such as hereditary cancer risk assessment, tumor profiling, prenatal and reproductive health, and pharmacogenomics for mental health conditions. Myriad’s products and services are organized across key business areas often described in its communications as Oncology, Women’s Health, and Pharmacogenomics.

Oncology and hereditary cancer testing

In its Oncology business, Myriad Genetics focuses on hereditary cancer testing and tumor profiling. The company’s disclosures identify the MyRisk Hereditary Cancer Test as a core product in hereditary cancer. MyRisk is described as a hereditary cancer test that has been expanded to include genes referenced in NCCN Clinical Practice Guidelines in Oncology and guidelines from the American Society of Clinical Oncology. These genes are associated with cancer risk and may have clear clinical actionability, supporting treatment decisions, surveillance planning, and family risk assessment across multiple cancer types.

The company also highlights tumor profiling products, including myChoice CDx, Prolaris, Precise Tumor, and Precise MRD. myChoice CDx is described in company materials as an FDA-approved homologous recombination deficiency (HRD) test mentioned in ASCO guidelines for selecting patients with ovarian cancer who may benefit from PARP inhibitors. Prolaris is referenced as a prostate cancer test within the Oncology portfolio. Precise Tumor and the broader Precise Oncology Solutions platform are positioned around tumor profiling and companion diagnostic and prognostic testing. Precise MRD is described as a molecular residual disease test that uses whole genome sequencing and personalized circulating tumor DNA (ctDNA) panels to detect very low levels of tumor-derived DNA, with applications in monitoring patients with cancers such as breast cancer and clear-cell renal cell carcinoma in research settings.

Women’s Health and reproductive genetics

In Women’s Health, Myriad Genetics offers tests that support cancer risk assessment and reproductive decision-making. Company communications describe MyRisk as an important tool for identifying individuals with elevated hereditary cancer risk in both affected and unaffected populations, including breast cancer risk assessment programs implemented through electronic medical record integrations and breast imaging centers.

Myriad also reports a prenatal testing portfolio that includes the FirstGene Multiple Prenatal Screen, Prequel Prenatal Screen, and Foresight Carrier Screen. Prequel is characterized in earlier descriptions as a noninvasive prenatal test, while Foresight is an expanded carrier screen. The company has disclosed updates to its Foresight Universal Plus Panel, including the addition of genes such as F8 and FXN and coverage of conditions recommended by professional medical societies for prenatal screening.

Pharmacogenomics and mental health

Myriad Genetics’ Pharmacogenomics business centers on the GeneSight Psychotropic test, which the company describes as a pharmacogenomic test for medications commonly prescribed for depression, anxiety, ADHD, and other psychiatric conditions. According to company communications, GeneSight provides information about how a patient’s genes may impact the way they metabolize or respond to certain psychiatric medications. Myriad cites published randomized controlled trials and meta-analyses indicating that access to GeneSight test results can be associated with improved response and remission rates in major depressive disorder compared to usual care.

Research, clinical evidence, and collaborations

Myriad Genetics frequently presents research at major scientific and medical conferences, reflecting an emphasis on generating clinical and analytical evidence for its tests. The company has announced multiple abstracts and poster presentations at meetings such as the San Antonio Breast Cancer Symposium and the National Society of Genetic Counselors Annual Conference. These presentations have covered topics including molecular residual disease testing in breast cancer, germline hereditary cancer mutations, polygenic risk assessment, tumor genomic profiling, prenatal cell-free DNA screening, carrier screening technologies, and educational initiatives for genetic counselors.

The company also engages in collaborations with other organizations. For example, Myriad has disclosed a strategic collaboration with SOPHiA GENETICS to develop a global liquid biopsy companion diagnostic testing solution for pharmaceutical companies, leveraging Myriad’s laboratory and regulatory capabilities. Another collaboration described by the company involves an integrated breast health risk platform with Clairity and MagView, combining Myriad’s MyRisk with RiskScore test with AI-based mammography risk assessment and breast imaging workflow software.

Financial reporting and capital structure

Myriad Genetics is listed on the NASDAQ under the ticker symbol MYGN and files periodic and current reports with the U.S. Securities and Exchange Commission. The company issues earnings releases and furnishes them on Form 8-K to report quarterly financial results and provide financial guidance. It also uses non-GAAP measures such as adjusted gross margin, adjusted operating expenses, adjusted EBITDA, and adjusted EPS, and explains these measures and their purposes in its investor communications.

In a Form 8-K filing, the company reported entering into a credit agreement that provides a term loan credit facility, with proceeds intended for working capital and general corporate purposes, including refinancing existing indebtedness. The agreement includes revenue-based financial covenants and is secured by substantially all of the assets of the company and certain subsidiaries, as described in the filing.

Corporate governance and leadership changes

Myriad Genetics discloses changes in its executive leadership through Form 8-K filings. Recent filings describe the departure of a former Chief Financial Officer, the appointment of a new Chief Financial Officer, and the designation of that executive as principal accounting officer. The filings outline related employment and separation agreements, including severance terms and equity award vesting provisions, as well as standard confidentiality, invention assignment, and restrictive covenant agreements.

Role in precision medicine

Across its Oncology, Women’s Health, and Pharmacogenomics businesses, Myriad Genetics positions itself as a company that uses molecular and genomic information to support more personalized medical decisions. Its tests are described as tools that can help clinicians identify individuals at increased risk of disease, select targeted therapies, plan surveillance strategies, and tailor medication choices based on genetic factors. Through ongoing research presentations, product updates, and collaborations, the company emphasizes the integration of molecular diagnostics into routine clinical workflows.